Psoriasis | Access & Reimbursement | Detailed, Expanded Analysis - Top 5 European Markets (EU)

Publish date: June 2019

Login to access report

MARKET OUTLOOK

The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and Otezla (Celgene) now face stiff competition from IL-17 inhibitors Cosentyx (Novartis), Taltz (Eli Lilly), and Kyntheum (Leo Pharma), as well as from the highly efficacious first-in-class IL-23 inhibitor Tremfya (Janssen). Competition is set to be intensified by additional IL-17 and IL-23 inhibitors waiting in the wings alongside the first TYK2 inhibitor, and, crucially, overall brand dominance is threatened by increasing biosimilar uptake. This research analyzes the complex reimbursement and market access environment for psoriasis treatment as key therapies jostle for prime positioning, and payers and prescribers strive to balance clinical superiority with cost effectiveness.

QUESTIONS ANSWERED

  • How do reimbursement terms for targeted psoriasis agents vary across the top European markets? How do payers regulate use of these premium-priced drugs?
  • How do prescribing patterns differ between and within the countries under study? What factors most influence uptake? How impactful is payer policy?
  • How has the increasing availability of biosimilars altered payer preferences and mandates? What is the actual impact of biosimilar availability on prescribing?
  • What key access and uptake challenges do emerging agents face in an increasingly crowded market? What lessons have been learnt? How can optimal product positioning be achieved?

GEOGRAPHY

France, Germany, Italy, Spain, United Kingdom

PRIMARY RESEARCH

  • Survey of 252 dermatologists across the top 5 European markets (50 per country)
  • Interviews with 10 payers across the top 5 European markets (2 per country)

KEY DRUGS COVERED

Enbrel, Humira, Remicade, Stelara, Otezla, Cosentyx, Taltz, Kyntheum, Tremfya, bimekizumab, mirikizumab, tildrakizumab, risankizumab, BMS-986165

CONTENT HIGHLIGHTS

  • Actionable recommendations to optimize market access
  • Market access success and stumbles
  • Market access roadblocks
  • Pricing and reimbursement dynamics
  • Impact of payer policy and coverage on prescribing
  • Market access outlook for emerging therapies

Product Description

European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers, examining reimbursement dynamics and evaluating the impact of payer policy on prescribing behavior.

Table of contents

  • Detailed, Expanded Analysis - Top 5 European Markets (EU)
    • Access & Reimbursement Psoriasis Top 5 European Market July 2019

Author(s): Micaela Vidal-Taylor, PhD; Yingdee Unhavaithaya

Micaela Vidal-Taylor is an Analyst in the Global Market Access team at DRG, with a particular focus on the EU5. In this role, she produces primary and secondary research-based reports and other insights designed for decision markets within the biopharmaceutical industry. Micaela holds a PhD in Clinical Medicine from Imperial College London, for which she received a full scholarship from the British Heart Foundation. She also holds a masters degree in Biomedical Sciences from Imperial College London in which she achieved a Distinction, and a masters degree in Pharmacology from the University of Oxford.

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.